PUBLIC COMPANY
save$VIRVir Biotechnology, Inc.
$VIR10.65+1.33%San Francisco, CA, USupdated 1d ago
community read0 votes
pipeline
5
marketed
0
phase 3
3
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
2Phase 13Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- phase2Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
- phase2Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
- phase1Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
- phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
- phase2A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
- phase2A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 6, 26SELLDe Backer Marianne· President and CEO−$664K↗
🐶 Hiring Signal
next earnings Nov 4, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 54m ago
Found something off?
comments(0)
5-min edit window · permanent after that